PROGRAM BOOKLET - ti.ch · PROGRAM BOOKLET TRAFO Baden, Switzerland November 7 ... Robert Genta,...
34
JOINT ANNUAL MEETING OF THE SWISS AND AUSTRIAN SOCIETIES OF PATHOLOGY PROGRAM BOOKLET TRAFO Baden, Switzerland November 7 – 9, 2013
Transcript of PROGRAM BOOKLET - ti.ch · PROGRAM BOOKLET TRAFO Baden, Switzerland November 7 ... Robert Genta,...
JOINT ANNUAL MEETING OF THE SWISS AND AUSTRIAN SOCIETIES OF PATHOLOGY
PROGR
AMBO
OKL
ETTR
AFO B
aden
, Sw
itzerland
Nove
mbe
r 7 – 9, 2
013
ORG
ANIZAT
ION Gad Singer, Baden, Switzerland (President of the meeting)
Laura Rubbia-Brandt, Genève, Switzerland (President of the SSPath/SGPath) Sigurd Lax, Graz, Austria (President of the ÖGP/Austrian Division of the IAP)Pierre-André Diener, St.Gallen, Switzerland (Secretary of the SSPath/SGPath)Kurt Prein, Graz, Austria (Secretary of the ÖGP/Austrian Division of the IAP)Lukas Bubendorf, Basel, Switzerland (Scientific advisor)Cord Langner, Graz, Austria (Scientific advisor)Alessandro Lugli, Bern, Switzerland (Scientific advisor)Felix Offner, Feldkirch, Austria (Scientific advisor)Hermann Rogatsch, Klagenfurt, Austria (Scientific advisor)
Local organizing committeeGad SingerSylvia StadlmannUwe RogelBettina Köppli
Institut für PathologieKantonsspital BadenIm ErgelCH-5404 BadenSwitzerland
Phone: +41 56 486 39 01Fax: +41 56 486 39 19Mail: [email protected]
Page
2
WEL
COMEDear colleagues
We cordially welcome you to the Joint Annual Meeting of the Swiss and Austrian Societies of Pathology in Baden, Switzerland.
We will hold this meeting in the spirit of cooperation and friendship in order tobroaden our professional skills and to develop our ties.Our scientific advisors in close cooperation with the local organizing committeehave put together an exciting and varied scientific program in order to meet thebroad needs of the participants. We are proud that many well-known international speakers have accepted our invitation.
We will focus on important recent developments in the fields of gastrointestinal, gynecologic, pulmonary, urologic and molecular pathology.The scientific symposia will be supplemented by oral and poster presentationsof research studies from different fields of pathology.
We hope you will enjoy the program.
Welcome to Baden
Prof. Dr. med. Gad Singer Prof. Dr. Laura Rubbia-Brandt President of the meeting President of the SSPath/SGPath
Prof. Dr. med. Sigurd LaxPresident of the ÖGP/Austrian Division of IAP
Page
3
LIST
OF
INVITE
D SP
EAKE
RS
Page
4
Lukas BubendorfLars EgevadJonathan EpsteinRobert GentaPaul KomminothHeinz-Josef LenzCord LangnerGlenn McCluggageElizabeth MontgomeryIris NagtegaalEsther OlivaSven PernerAurel PerrenSolange PetersJaime PratRobert RiddellNeil A. Shepherd
WEL
COME
Page
3AC
KNOWLE
DGEM
ENTS
Page
5
PROGR
AM, TH
URS
DAY, N
OVE
MBE
R 7, 2
013
Page
6
08.30 – 12.00 Workshop Endocrine Pathology Paul Komminoth and Aurel Perren, Switzerland Sponsor: Novartis Oncology
08.30 – 10.00 Part I Workshop Endocrine Pathology
10.00 – 10.30 Coffee break
10.30 – 12.00 Part II Workshop Endocrine Pathology
Lunch for Workshop participants
13.00 – 13.15 Official Welcome Ständerätin Pascale Bruderer Wyss, Baden and President of the meeting
13.15 – 16.15 Symposium Urologic Pathology Chairs: K. Mertz, Liestal M. Pusztaszeri, Genéve
13.15 – 13.45 Mesenchymal lesions of the prostate Jonathan Epstein, USA
13.45 – 14.15 Controversies in specimen processing and reporting of prostate cancer Lars Egevad, Sweden
14.15 – 14.45 First results from next generation sequencing efforts in prostate cancer research Sven Perner, Germany
14.45 – 15.45 Coffee Break, Exhibition and Poster Walk
15.45 – 16.15 Update on the Gleason Grading System Jonathan Epstein, USA
PROGR
AM, TH
URS
DAY, N
OVE
MBE
R 7, 2
013
Page
7
16.30 – 17.20 A glimpse into Molecular Pathology Chairs: J. Diebold, Luzern S. Dirnhofer, Basel
16.30 – 17.00 MET meets lung cancer – a new therapeutic target on the horizon Sponsor: Roche Solange Peters and Lukas Bubendorf, Switzerland
17.00 – 17.20 Droplet Digital PCR - Molecular Biology in High Resolution Sponsor: Biorad Pia Scheu, Switzerland
17.20 – 18.20 Free paper presentations I Chairs: R. Grobholz, Aarau P. Wild, Zürich
18.30 – 19.30 Meeting of the Institute Directors
19.30 Get-together party
Page
8
08.00 – 09.00 Free paper presentations II Chairs: G. Cathomas, Liestal A. Weber, Zürich
09.00 – 11.30 Symposium Gynecologic Pathology Chairs: S. Lax, Graz Z. Varga, Zürich
09.00 – 09.30 Sex cord stromal tumors of the ovary Glenn McCluggage, UK
09.30 – 10.30 Coffee Break, Exhibition and Poster Walk
10.30 – 11.00 Germ cell tumors of the ovary Jaime Prat, Spain
11.00 – 11.30 Mesenchymal tumors of the uterus Esther Oliva, USA
12.00 – 13.30 Lunch Symposium Sponsors: Qiagen and Amgen Chairs: W. Jochum, St. Gallen L. Mazzucchelli, Locarno
12.00 – 12.30 Business Meeting of the Swiss Society of Molecular Pathology (SGMP) Wolfram Jochum, Switzerland
12.30 – 13.00 Molecular pathology of colorectal carcinoma – what is next? Heinz-Josef Lenz, Los Angeles, USA
13.00 – 13.30 Prognostic and predictive factors in colorectal carcinoma Iris Nagtegaal, The Netherlands
14.00 – 15.00 Part I Symposium Gastrointestinal Pathology Chairs: A. Lugli, Bern F. Offner, Feldkirch
14.00 – 14.30 Gastric atrophy and Atrophic Gastritis: from the biopsy to the disease Robert Genta, USA
PROGR
AM, FR
IDAY
, NO
VEMBE
R 8, 2
013
Page
9PR
OGR
AM, FR
IDAY
, NO
VEMBE
R 8, 2
01314.30 – 15.00 Small Intestinal Pathology - „All In A Day’s Work!“
Elizabeth Montgomery, USA
15.00 – 16.00 Coffee Break, Commercial Exhibition and Poster Walk
16.00 – 17.30 Part II Symposium Gastrointestinal Pathology Chairs: H. Feichtinger, Wien L. M. Terracciano, Basel
16.00 – 16.30 Histomorphological aspects of colorectal cancer in daily diagnostic practice Cord Langner, Austria
16.30 – 17.00 Dysplasia in inflammatory bowel disease Robert Riddell, Canada
17.00 – 17.30 The changing role of pathology in the management of Barrett’s oesophagus Neil Shepherd, UK
17.45 – 18.45 Free paper presentations III followed by presentation of poster prizes (sponsored by ZEISS and Basys Data) Chairs: L. de Leval, Lausanne M. Rössle, Zürich Poster prize committee: H.-A. Lehr, Friedrichshafen I. Zlobec, Bern S. Stadlmann, Baden D. Baumhoer, Basel
19.30 Gala dinner
Page
10
PROGR
AM, SA
TURD
AY, NO
VEMBE
R 9, 2
013 08.30 – 10.00 General Assembly of the Swiss Society of Pathology
Pierre-André Diener and Laura Rubbia-Brandt, Switzerland (TRAFO Main Hall) Business meeting of the Austrian Society of Pathology Sigurd Lax and Kurt Prein, Austria (Ampere)
10.00 – 10.30 Coffee break
10.30 – 13.00 Slide Seminar: Mesenchymal Tumors of the Urogenital and Gastrointestinal Tracts
Elizabeth Montgomery, USA Esther Oliva, USA Jonathan Epstein, USA Glenn McCluggage, UK Neil Shepherd, UK Robert Riddell, USA
13.00 End of the meeting
Start sequencing now at lifetechnologies.com/iontorrent
FOR RESEARCH USE ONLY. Not for use in diagnostic procedures. ©2013 Life Technologies Corporation. All rights reserved. The trademarks mentioned herein are the property of Life Technologies Corporation and/or its affiliate(s) or their respective owners. CO33501 0413
EVERYONE DESERVES A CHANCE TO
BREAK THROUGHIon Torrent™ next-generation sequencing solutions make decoding genes faster, easier, and more accessible—bringing sequencing into more labs, in more places, and in more ways than ever before.
N
NH2
H
C
CH
OH
N
C
N
C
NH2
H
C
CH
OH
N
C
C
N
C
O
H
C
C
H3C H
OH
N
C
N
C
NH2
C
C NN
HH
N H
H
C
N
C
NH2
H
O
N
C
N
C
O
H
C
C
H3C H
N
C
N
C
O
H
C
C
H
O
N
C
H
NH2
H
N
N
H
C
C
ist ein speziell für Brustkrebspatientinnen entwickelter Prognosetest. Er wurde mit dem Evidenzlevel 1 in die Behandlungsleitlinien der Arbeitsgemeinschaft Gynäkologi-sche Onkologie (AGO) aufgenommen. EndoPredict kann das Risiko einer frühen und – im Gegensatz zu vielen älteren Methoden – auch das Risiko der späten Metastasierung vorhersagen. Nur bei Patientinnen mit einer sehr guten Langzeitprognose kann auf eine Chemotherapie verzichtet werden. Als erster Test seiner Art wird der EndoPredict direkt in der örtlichen Pathologie als ärztliche Leistung angeboten. Das Ergebnis kann bereits nach einem Tag vorliegen und ermöglicht eine zeitnahe Planung der weiteren Therapieschritte.
www.endopredict.com
Neuerkrankungen jährlich in der Schweiz5.000
DOCh wELChE PATiENTiN BENöTiGT kEiNE ChEMOThERAPiE?DiE ANTwORT LiEGT iN DER TuMORBiOLOGiE.
ÜBER
FREE
PAP
ER, ORA
L PR
ESEN
TATIONS
, SE
SSIO
N I
THURS
DAY, N
OVE
MBE
R 7, 2
013, 17.20
– 18.20
FREE
PAP
ER, ORA
L PR
ESEN
TATIONS
, SE
SSIO
N I FP01
Heterogeneity of ERG expression in core needle biopsies of patients with early prostate cancer
K.D. Mertz 1, M. Horcic 2, S. Hailemariam 2, A. D’Antonio 3, S. Dirnhofer 4, A. Hartmann 5, A. Agaimy 5, S. Eppenberger-Castori 4, E. Obermann 4, G. Cathomas 1, L. Bubendorf 4
1 Institute for Pathology Liestal, Cantonal Hospital Baselland, Liestal, Switzerland 2 Institut für histologische und zytologische Diagnostik AG Aarau, Aarau, Switzerland 3 Department of Medicine and Surgery, University of Salerno, Italy 4 Institute for Pathology, University Hospital Basel, Basel, Switzerland 5 Department of Pathology, University of Erlangen-Nuremberg, Erlangen, Germany
FP02Everolimus as first-line therapy in metastatic castration resistant prostate cancer: results from a phase II trial (SAKK 08/08) J. Rüschoff 1, Q. Zhong 1, W. Jochum 2, A. Templeton 2, V. Dutoit 3, R. Cathomas 4, C. Rothermund 2, D. Bärtschi 5, C. Dröge 6, O. Gautschi 7, M. Borner 8, E. Fechter 9, F. Stenner 1, R. Winterhalder 10, B. Müller 11, R. Schiess 12, G. Thalmann 7, E. Liabotis 13, R. Aebersold 14, P. Y. Dietrich 3, D. Klingbiel 5, S. Gillessen 2, P. J. Wild 1
1 University Hospital Zurich, Zürich 2 Cantonal Hospital St. Gallen, St. Gallen3 University Hospital Geneva, Laboratory of Tumor Immunology, Genf 4 Cantonal Hospital Graubünden, Chur5 SAKK Coordinating Center, Bern 6 University Hospital Basel, Basel7 University Hospital Berne, Bern 8 Hospital Biel, Biel 9 Cantonal Hospital Winterthur, Winterthur
10 Cantonal Hospital Lucerne, Luzern 11 Cantonal Hospital Aarau, Aarau
12 ProteoMediX AG, Schlieren 13 Ventana Medical Systems, Tucson 14 ETH Zurich, Institute of Molecular Systems Biology, Zürich
FP03Validation of chromogenic in situ hybridization for the diagnosis of ALK rearrangements in non small cell lung cancer.
Page
14
FREE
PAP
ER, ORA
L PR
ESEN
TATIONS
, SE
SSIO
N I
Page
15
K.-F. Deml 1,3, K. Schmitz 1,2, M. Meiboom 4, E. Binot 1, S. Merkelbach-Bruse 1, R. Büttner 1, S. Hauke 4, H.-U. Schildhaus 1,2.
1 Institute of Pathology, University Hospital Cologne, Cologne, Germany, as part of the Lung Cancer Group Cologne (LCGC)
2 Institute of Pathology, University Hospital Göttingen, Göttingen, Germany3 Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland4 ZytoVision GmbH, Bremerhaven, Germany
FP04Implementation of NGS in Lung Cancer Diagnostics at the University Hospital Zurich
M. P. Rechsteiner 1, Q. Zhong 1, A. Bohnert 1, A. Soltermann 1, Verena Tischler 1, Holger Moch 1, P. J. Wild 1
1 Institute of Surgical Pathology, University Hospital Zurich, Switzerland
FP05Next generation sequencing: Gene mutation profiling of adenosquamous carcinoma of the lung
S. C. Schäfer 1, S. Langsch 1, C. Schlup 1, M. Frattini 2, M. Gugger 3, A. Perren 1, E. Vassella 1
1 Institute of Pathology, University of Bern, Switzerland 2 Institute of Pathology, Locarno, Switzerland 3 Promed SA Laboratoire médical, Marly, Switzerland
FP06Lung neuroendocrine tumors: Where is PTEN?
S. Collaud 1, V. Tischler 2, A. Atanassoff 2, A. Perren 3, P. Komminoth 4, C. Oehlschlegel 5, H. Moch 2, W. Weder 1, A. Soltermann 2
1 Division of Thoracic Surgery2 Institute of Surgical Pathology, University Hospital, Zurich3 Institute of Pathology, University Hospital, Bern 4 Institute of Pathology, Triemli Hospital, Zurich 5 Institute of Pathology, Cantonal Hospital, St.Gallen, Switzerland
Dako Omnis ist da.Unsere neueste Lösung für die Immunhistologie und InSitu-Hybridisierung!
Wir zeigen Ihnen Dako Omnis live bei der diesjährigen gemeinsamen Jahrestagung der Österreichischen und Schweizerischen Gesellschaft für Pathologie in Baden.
Wir freuen uns auf Ihren Besuch an unserem Stand und heißen Sie herzlich willkommen.
Read more today at www.dako.com/omnis
50233 22AUG13 Dako Omnis - A generation Ahead_Advert_German versionA5.indd 1 28-08-2013 12:36:56
FREE
PAP
ER, ORA
L PR
ESEN
TATIONS
, SE
SSIO
N II
FRIDAY
, NO
VEMBE
R 8, 2
013, 0
8.00
– 0
9.00
FREE
PAP
ER, ORA
L PR
ESEN
TATIONS
, SE
SSIO
N II FP07
Genomic profiling of clonal tumor populations from hepatocellular carcinomas in non-cirrhotic liver reveals undetected population-specific genomic aberrations
M. Schlageter #, V. Perrina #, T. Lorber, L. Quagliata, M. L. Tornillo, M. Kovac, C. Ruiz, L. M. Terracciano
Institute for Pathology, University Hospital Basel, Basel, Switzerland# Equal contribution of the first two authors (M.S. and V.P.)
FP08Dysbalanced Keratins promote Steatohepatitis-associated Liver Carcinogenesis
K. Bettermann 1, A. Kuldeep Mehta 1, E. M. Lederer 1, C. Ernst 1, S. M. Kessler 1,2, K. Kojima 3, X. Cheng 3, Y. Hoshida 3, N. M. Bardessy 4, B. C. Fuchs 4, K. K. Tanabe 4, H. Müller 1, V. Svendova 5, M. G. Schimek 5, M. Mach 6, M. R. Speicher 6, C. Diwoky 7, A. Lipfert 7, V. Mahajan 1, C. Stumptner 1, A. Thüringer 1, L. F. Fröhlich 1, C. Smole 1, T. Stojakovic 8, M. Scheideler 9, K. P. R. Nilsson 10, T. Kolbe 11, T. Rülicke 11, T. Longerich 12, P. Schirmacher 12, T. M. Magin 13, P. Strnad 14, C. D. Fuchs 15, M. Trauner 15, R. Spilka 16, A. K. Kiemer 2, A. Teufel 17, T. Maass 17, N. Grabe 18, K. M. Müller 19, M. Themanns 19, R. Moriggl 19, J. S. Campbell 20, S. Thorgeirsson 21, M. Pasparakis 22, J. Stauffer 23, M. Karin 24, J. M. Llovet 25,26, K. Zatloukal 1, H. Denk 1, C. Lackner 1 and J. Haybaeck 1
1 Institute of Pathology, Medical University of Graz, Graz, Austria2 Department of Pharmacy, Pharmaceutical Biology, Saarland University, Saarbruecken, Germany
3 Liver Cancer Program, Tisch Cancer Institute, Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, USA
4 Center for Cancer Research, Massachusetts General Hospital, Harvard Medical School, Boston, USA
5 Institute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Austria
6 Institute of Human Genetics, Medical University of Graz, Graz, Austria7 Institute of Medical Engineering, Graz University of Technology, Graz, Austria 8 Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria
9 Institute for Genomics and Bioinformatics, Graz University of Technology, Graz, Austria
10 Department of Chemistry, Linköping University, Linköping, Sweden11 Biomodels Austria (Biat), University of Veterinary Medicine Vienna, Vienna, Austria12 Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany
Page
18
FREE
PAP
ER, ORA
L PR
ESEN
TATIONS
, SE
SSIO
N II
Page
19
13 Translational Centre for Regenerative Medicine Leipzig, University of Leipzig, Leipzig, Germany
14 Department of Internal Medicine III, University Hospital RWTH Aachen, Aachen, Germany
15 Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University Vienna, Vienna, Austria
16 Laboratory of Pathology, General Hospital Zams, Zams, Austria 17 Internal Medicine I, University Hospital Regensburg, Regensburg, Germany18 Hamamatsu Tissue Imaging and Analysis Center, BIOQUANT, National Center for
Tumor Diseases (NTC), Medical Oncology, University of Heidelberg, Heidelberg, Germany
19 Ludwig Boltzmann Institute for Cancer Research (LBI-CR), Vienna, Vienna, Austria20 Department of Medicine Pathology, University of Washington, USA 21 Center for Cancer Research NCI, NIH, Laboratory of Experimental Carcinogenesis,
Bethesda, USA22 Institute for Genetics, University of Cologne, Cologne, Germany23 Center of Cancer Research, NCI, Mouse Cancer Genetics Program, Genetic
Modifiers of Tumorigenesis Section, Frederick, USA24 Department of Pharmacology, Laboratory of Gene Regulation and Signal
Transduction, School of Medicine, University of California San Diego, La Jolla, USA25 Hepatocellular Carcinoma Translational Research Laboratory, Barcelona Clínic Liver
Cancer Group, Liver Unit, CIBERehd, Institut d‘Investigacions Biomèdiques, August Pi i Sunyer, Hospital Clínic Barcelona, Barcelona, Spain
26 Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain
FP09Possible role of Cdx2 in the serrated pathway of colorectal cancer characterized by BRAF mutation, high-level CpG Island Methylator Phenotype and mismatch repair-deficiency
H. Dawson 1,2, M. Helbling 2, E. Karamitopoulou 1,2, V. H. Koelzer 1,2, A. Lugli 1,2, I. Zlobec 2
1 Clinical Pathology Division and 2 Translational Research Unit, Institute of Pathology, University of Bern, Bern, Switzerland
*EntroGen’s analysis kits require a Real-Time PCR instrument capable of detecting FAM™ and VIC® fluorescent probes.
All the reagents required for the PCR amplification/detection, as well as validated reaction controls, are included in the kit.
BRAF-Inhibitor Resistance Detection Kiton your* Real-Time PCR Instrument
BRAF-Inhibitor Resistance DNA Detection Kit Gene Name Assay Type Detects
NRAS Mutation Analysis (DNA) G12D, G13R, Q61K, Q61R, Q61L
AKT1 Mutation Analysis (DNA) Q79K
BRAF Copy Number Variation (DNA) Gene copy number
new!
BÜHLMANN Laboratories AG Phone +41 61 487 12 12Baselstrasse 55 Fax +41 61 487 12 34CH–4124 Schönenbuch/Basel [email protected] www.buhlmannlabs.ch
Gene Name Assay Type Detects
BRAF Splice Variant (RNA) p61BRAF 2-10, 2-8, 4-10, 4-8
PDGFRβ Expression Analysis (RNA) PDGFRβ Overexpression
BRAF-Inhibitor Resistance RNA Detection Kit new!
Page
21
FREE
PAP
ER, ORA
L PR
ESEN
TATIONS
, SE
SSIO
N II
FP10ZEB2 CpG promoter methylation in colorectal cancer is associated with lymph node metastases and invasion in KRAS wild-type patients
I. Zlobec 1, M. Helbling 1, H. Dawson 1,2, V. H. Koelzer 1,2, E. Karamitopoulou 1,2, A. Lugli 1,2
1 Translational Research Unit (TRU) and 2 Clinical Pathology Division, Institute of Pathology, University of Bern, Murtenstrasse 31, Bern, 3010, Switzerland
FP11Influence of KRAS mutations on outcome in patients with curatively resected stage III colon cancer treated with adjuvant chemotherapy
M. Nucifora 1, S. De Dosso 2, A. Spitale 3, N. Sahnane 1, M. E. Riveiro 4, V. Bertolini 5, E. Bucci 5, S. Crippa 1, P. Saletti 2, L. Mazzucchelli 1, M. Frattini 1
1 Institute of Pathology, Via In Selva 24, Locarno, Switzerland 2 Oncology Institute of Southern Switzerland, Bellinzona, Switzerland3 Ticino Cancer Registry, Institute of Pathology, Via In Selva 24, Locarno, Switzerland.
4 Beaujon University Hospital, Clichy, France 5 Istituto Ospedaliero MultiMedica, Castellanza, Italy
FP12Detection of Pivotal Molecular Targets in Gastrointestinal Stromal Tumours via High Resolution Melting Analysis.
R. Madlener 1,2, A. Boesl 2, R. Stockinger 2, F. A. Offner 2
1 Department of Pathology, Landeskrankenhaus Feldkirch, Austria 2 Department of Pathology, Cantonal Hospital Luzern, Switzerland
KRAS & BRAF StripAssays®
Gewerbestrasse 25, 4123 Allschwil • Phone: (+41) 61 482 2070 • [email protected] • www.endotell.chViennaLab EndotellManufacturer Exclusive distributor in Switzerland
Identification of relevant mutations in the KRAS & BRAF genes to optimize patient-specific cancer therapies
• Simple protocol for complex diagnostic questions• Manual or automated processing• No expensive lab equipment required• CE labelled kits
BRAF 600/601
BRAF
KRAS-BRAF
KRAS
KRAS 12/13/61
Val
V600E (c.1799T>A)
Codon 12: Ala, Arg, Asp, Cys, Ile, Leu, Ser, Val; Codon 13: Asp, Cys;
Codon 12: Ala, Arg, Asp, Cys, Ile, Leu, Ser, Val; Codon 13: Asp, Cys
Codon 12: Ala, Arg, Asp, Cys, Ile, Leu, Ser, Val; Codon 13: Asp, Cys; Codon 61: Arg, His, Leu
StripAssay® Mutations detected V600A (c.1799T>C), V600D (c.1799_1800TG>AT), V600E (c.1799T>A), V600E (c.1799_1800TG>AA), V600G (c.1799T>G), V600K (c.1798_1799GT>AA), V600M (c.1798G>A), V600R (c.1798_1799GT>AG), K601E (c.1801A>G)
For more information visit us at www.viennalab.com
V600E (c.1799T>A)
Werbung Magazin Schweiz 2013-09-30.indd 1 08.10.2013 17:20:36
FREE
PAP
ER, ORA
L PR
ESEN
TATIONS
, SE
SSIO
N III
FRIDAY
, NO
VEMBE
R 8, 2
013, 17.45
– 18.45
FREE
PAP
ER, ORA
L PR
ESEN
TATIONS
, SE
SSIO
N III
Page
24
FP13Integrative Genomic and Molecular Pathology Profiling of Interactions between Tumor Cells and Inflammatory Microenvironment in Hormone Receptor Negative Breast Cancer
M. Kovac 1, S. Romagnoli 2, D. Maisel 2, A. Belousov 2, O. Spleiss 3, F. Feuerhake 2, F. Gaire 2, S. Eppenberger 1, L. M. Terracciano 1
1 Institute for Pathology, University Hospital Basel, Basel, Switzerland2 Roche Pharma Research and Early Development (pRED), Penzberg, Germany3 Roche Pharma Research and Early Development (pRED), Basel, Switzerland
FP14Cyclin D1-positive diffuse large B-cell lymphomas with CYCLIN D1 gene rearrangements: clinical, morphological, phenotypic and genetic evidence for their existence
D. Juskevicius 1, C. Ruiz 1, S. Dirnhofer 1, A. Tzankov 1
1 Institute of Pathology, University Hospital Basel, Switzerland
FP15Comprehensive evaluation of a new technology for simultaneous high quality preservation of biomolecules and morphology in tissues K. F. Becker 1, D. Groelz 2, S. Gündisch 1, K. Kashofer 3, M. Kap 4, U. Oelmüller 2, P. Regitnig 3, P. Riegman 4, C. Viertler 3, P. Verderio 5, K. Zatloukal 3
1 Institute of Pathology, Technical University Munich, Munich, Germany 2 Qiagen GmbH, Hilden, Germany 3 Institute of Pathology, Medical University of Graz, Graz, Austria 4 Department of Pathology, Erasmus Medical Center, Rotterdam, The Netherlands 5 Unit of Medical Statistics and Biometry, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
FREE
PAP
ER, ORA
L PR
ESEN
TATIONS
, SE
SSIO
N III
Page
25
FP16The use of patient derived malignant effusions as in vitro models for a personalized healthcare-approach in anticancer therapy
T. Vlajnic 1, C. Ruiz 1, L. Arabi 1, S. Wyttenbach 1, B. Baschiera 1, S. Rothschild 3, S. Kustermann 2, A. Zippelius 3, A. Roth 2, L. Bubendorf 1
1 Institute of Pathology, University Hospital Basel, Basel, Switzerland2 Non-Clinical Safety, Pharma Research, Hoffmann-La Roche Ltd, Basel, Switzerland
3 Department of Medical Oncology, University Hospital Basel, Basel, Switzerland
FP17EGFR regulation by NEU3 sialidase may have clinical impact
A. Riva 1, A. Mozzi 2, C. Difrancesco 1, M. Forcella 2, F. Molinari 1, P. Fusi 2, E. Monti 2, L. Mazzucchelli 1, M. Frattini 1
1 Laboratory of Molecular Pathology, Institute of Pathology, Locarno, Switzerland2 Department of Biotechnologies and Biosciences, Univeristy of Milano-Bicocca, Milan, Italy
FP 18Implementing Next Generation Sequencing: More than just Plug and Play
A. Paasinen Sohns 1, A. Frank 1 and G. Cathomas 1
1 Institute of Pathology, Kantonsspital Baselland, Liestal, Switzerland
Der Moment, in dem perfekte Technik Gewissheit bringt. Für diesen Moment arbeiten wir.
Carl Zeiss AG Mikroskopie8714 FeldbachTel. 055 254 75 00 Email: [email protected] www.zeiss.ch/microscopy
// GEWISSHEIT MADE BY CARL ZEISS
Page
27
FP19An improved ex vivo model for hypoxic microenvironment investigation of prostate cancer
N. J. Rupp 1, F. Falkner 1,2, R. Largo 3, H. Moch 1, M. Tremp 4, T. Sulser 5, G. Kristiansen 6, M. Müntener 5, P. J. Wild 1
1 Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland2 Institute of Pathology, Cantonal Hospital Winterthur, Winterthur, Switzerland3 Department of Urology, City Hospital Triemli, Zurich, Switzerland4 Department of Plastic, Reconstructive and Aesthetic Surgery, University Hospital Basel, Basel, Switzerland
5 Department of Urology, University Hospital Zurich, Zurich, Switzerland6 Institute of Pathology, University Hospital Bonn, Bonn, Germany
FP20MUC1 in lymph node metastases predicts survival in advanced prostate cancer V. Genitsch ¹, I. Zlobec 1, G. Thalmann ², A. Fleischmann ¹ 1 Translational Research Unit (TRU), University of Bern, Murtenstrasse 31, Bern, Switzerland
FP21Evaluation of the role of DOG1 in metastasizing bladder cancer
J. R. Gsponer 1, M. Verdana 4, T. Vlajnic 1, C. A. Rentsch 5, A. Krause 1, A. Fleischmann 2, G. N. Thalmann 3, T. Zellweger 4, A. Bachmann 5, C. Ruiz 1, L. Bubendorf 1
1 Institut für Pathologie, Universitätsspital Basel, Switzerland2 Institut für Pathologie, Universität Bern (current affiliation: Pathologie, Kantonsspital Münsterlingen) , Switzerland
3 Urologische Universitätsklinik, Bern, Switzerland4 Urologische Klinik, St. Clara Spital Basel, Switzerland5 Urologische Klinik, Universitätsspital Basel, Switzerland
FREE
PAP
ER, PO
STER
PRE
SENT
ATIO
NS
Interdisziplinäre Tumorboards in der Cybermedical Community inkl. Live-Übertragung der Patho-Bilder direkt von einer Toshiba Full HD Kamera
Besuchen Sie uns an der Messe vor Ort in Baden oder auf unserer Webseite: www.cybermedical.ch / www.toshiba.ch/ics
A
Pathologie A Pathologie B(Spezialist)
FREE
PAP
ER, PO
STER
PRE
SENT
ATIO
NSPa
ge 2
9
FP22Characterization of the inflammatory infiltrate in bacterial pneumonia in young and elderly patients
C. Giefing-Kroell 1, B. Grubeck-Loebenstein 1, T. Menter 2, A. Tzankov 2
1 Institute of Biomedical Ageing Research, Austrian Academy of Sciences, Innsbruck, Austria
2 Institute of Pathology, University Hospital Basel, Switzerland
FP23An unexpected cause of diffuse alveolar haemorrhage in an immunosuppressed kidney transplant patient
L. Bubendorf 1, D. K. Jahn 2, S. Savic 1, M. Schlageter 1, M. Tamm 1, A. Tzankov 1, M. Wiese 3
1 Institute for Pathology, University Hospital Basel, Basel, Switzerland2 Clinic of Pneumology, University Hospital Basel, Basel, Switzerland 3 Clinic of Thoracic Surgery, University Hospital Basel, Basel, Switzerland
FP24An apoptosis-driven pathway to hepatocarcinogenesis in mice and men
Y. Böge 1, F. Böhm 1, J. Friemel 1, L. Frick 1, J. Mertens 2, B. Müllhaupt 2, R. Maire 1, R. Boger 3, H. Schulze-Bergkamen 3, M. Heikenwälder 1,4, A. Weber 1
1 Institute of Surgical Pathology, UniversityHospital Zurich, Switzerland2 Institute of Hepatology, UniversityHospital Zurich, Switzerland3 Nationales Centrum für Tumorerkrankungen (NCT) Heidelberg, Germany4 Institute of Virology, Helmholtz Center Munich/ TU Munich, Germany
Page
30
FREE
PAP
ER, PO
STER
PRE
SENT
ATIO
NS FP25SH2D4A is a tumor suppressor gene frequently downregulated in hepatocellular carcinoma
M. Andreozzi 1, L. Quagliata 1, M. Kovac 1, L. Tornillo 1, Z. Makowska 2, M. Heim 2, K. Heinimann 3, S. Piscuoglio 3*, L. M. Terracciano 1*
1 Institute of Pathology, University Hospital of Basel, Basel, Switzerland2 Department of Biomedicine, Hepatology Laboratory, University of Basel, Basel, Switzerland
3 Research Group Human Genetics, Department of Biomedicine, University of Basel, and Division of Medical Genetics, University Children‘s Hospital, Basel, Switzerland
FP26The role of HOX genes network and associated lncRNAs in Hepatocellular carcinoma
Luca Quagliata 1, Matthias S. Matter 1,2, Salvatore Piscuoglio 1,3, Leila Arabi 1, Christian Ruiz 1, Alfredo Procino 4, Michal Kovac 1, Francesca Moretti 5, Zuzanna Makowska 6, Tujana Boldanova 6, Jesper B. Andersen 2, MonikaHämmerle 7, Luigi Tornillo 1, Markus H. Heim 6, Sven Diederichs 7, Clemente Cillo 4 and Luigi M. Terracciano 1
1 Institute of Pathology, Molecular Pathology Division, University Hospital of Basel, Basel, Switzerland
2 Laboratory of Experimental Carcinogenesis, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, USA
3 Research Group Human Genetics, Department of Biomedicine, University of Basel and Division of Medical Genetics, University Children‘s Hospital, Basel, Switzerland
4 Department of Clinical Medicine and Surgery, Federico II University Medical School, Naples, Italy
5 Department of Biomedicine, Institute of Biochemistry and Genetics, University of Basel, Basel, Switzerland
6 Department of Biomedicine, Hepatology Laboratory, University of Basel, Basel, Switzerland
7 Helmholtz-University-Group “Molecular RNA Biology & Cancer”, German Cancer Research Center (DKFZ) and Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany
Page
31
FREE
PAP
ER, PO
STER
PRE
SENT
ATIO
NSFP27Potential role of h-prune in hepatocarcinogenesis
S. Stadlmann 1, L. Tornillo 2, M. Roncalli 3, M. Zollo 4, L. M. Terracciano 2
1 Institute of Pathology, Kantonsspital Baden AG, Switzerland 2 Institute of Pathology, University Hospital Basel, Basel, Switzerland
3 Department of Pathology, Humanitas Clinical Institute of Rozzano, University of Milan, Milan, Italy
4 Centro di Ingegneria Genetica e Biotecnologia Avanzate, CEINGE, Naples, Naples, Italy
FP28Biliary/progenitor-cell markers and liver-specific Wnt target genes define distinct subgroups of hepatocellular carcinoma
L. D. Frick 1, Y. Boege 1,2, F. Böhm 1, J. Friemel 1, L. Quagliata 3, L. M. Terracciano 3, M. Heikenwälder 4,5, A. Weber 1
1 Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland 2 Institute of Neuropathology, University Hospital Zurich, Zurich, Switzerland 3 Institute of Pathology, University Hospital Basel, Basel, Switzerland4 Institute of Virology, Helmholtz Zentrum München für Gesundheit und Umwelt, Munich, Germany
5 Institute of Virology, Technische Universität München, Munich, Germany
FP29A souvenir from the Seychelles
S. Tschopp 1, J. Beer 1, F. Eigenmann 1, S. Stadlmann 2
1 Department of Internal Medicine, 2 Institute of Pathology, Kantonsspital Baden AG, Switzerland
Page
33
FREE
PAP
ER, PO
STER
PRE
SENT
ATIO
NSFP30Adhesion molecule expression pattern in primary sclerosing cholangitis and disease controls
M. J. Pollheimer 1,2, P. Fickert 1,2, T. H. Karlsen 3 and M. Trauner 4
1 Institute of Pathology, Medical University of Graz, Austria 2 Laboratory of Experimental and Molecular Hepatology, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz, Austria
3 Norwegian PSC Research Center, Medical Department, Oslo University Hospital Rikshospitalet, Oslo, Norway
4 Hans Popper Laboratory of Molecular Hepatology, Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Austria
FP31Decreased CD8+ lymphocytes / Tumor-budding ratio is associated with metastasis and venous invasion in pancreatic ductal adenocarcinoma (PDAC)
E. Diamantis-Karamitopoulou 1,2, A. Lugli 1,2, B. Gloor 3, A. Perren 1,2, I. Zlobec 2
1 Clinical Pathology Division and 2 Translational Research Unit, Institute of Pathology, University of Bern, Bern, Switzerland
3 Department of Visceral Surgery, Insel University Hospital, Bern, Switzerland
FP32 Loss of Raf-1 kinase inhibitor protein (RKIP) promotes epithelial mesenchymal transition (EMT) in form of tumor budding in pancreatic ductal adenocarcinoma (PDAC)
E. Diamantis-Karamitopoulou 1,2, I. Zlobec 2, B. Gloor 3, A. Lugli 1,2, A. Perren 1,2
1 Clinical Pathology Division and 2 Translational Research Unit, Institute of Pathology, University of Bern, Bern, Switzerland
3 Department of Visceral Surgery, Insel University Hospital, Bern, Switzerland
www.mediteservice.ch
Medite Service AGBinzstrasse 5CH-8953 DietikonTel. +41 44 744 30 20Fax +41 44 744 30 [email protected] www.mediteservice.ch
StarFrost®
Objektträger
WärmetechnikHochleistungs-
Luftreiniger
TPC 15 Duo / Trio
KombiTCA 44-720
Histologie - Zytologie - Pathologie
CO.RE-FRONTArchivsysteme
Quick Ray® Manual Tissue Microarrayer
Paraffin Block Trimmer
intelliPATH FLX™
NxGen(HIER)
Multiplex IHC
Immunhistochemie
Chromogene
TES Valida
Page
35
FREE
PAP
ER, PO
STER
PRE
SENT
ATIO
NSFP33Intratumoural budding (ITB) in preoperative biopsies predicts the presence of lymph node and distant metastases in colon and rectal cancer patients
H. Dawson 1,3, M. Hädrich 2, V. H. Koelzer 1,3, M. Borner 4, Makhmudbek Mallaev 1,2, B. Schnüriger 2, D. Inderbitzin 2, I. Zlobec 1, A. Lugli 1,3
1 Translational Research Unit (TRU), Institute of Pathology, University of Bern, Switzerland
2 Department of Visceral Surgery and Medicine, Bern University Hospital, Bern, Switzerland
3 Clinical Pathology Division, Institute of Pathology, University of Bern, Switzerland4 Department of Oncology, Hospital Centre Biel, Biel, Switzerland
FP34TrkB expression in colorectal cancers highlights anoikis-resistance as a possible survival mechanism of tumor budding (EMT-like) cells
H. Dawson 1,2, V. H. Kölzer 1,2, E. Karamitopoulou 1,2, A. Lugli 1,2, I. Zlobec 2
1 Clinical Pathology Division and 2 Translational Research Unit, Institute of Pathology, University of Bern, Bern, Switzerland
FP35CpG promoter hypermethylation of CTNNB1 (β-catenin) and TWIST2 promote a high-grade tumor budding phenotype in colorectal cancer
I. Zlobec 1, M. Helbling 1, E. Karamitopoulou 1,2, H. Dawson 1,2, V. H. Koelzer 1,2, A. Lugli 1,2
1 Translational Research Unit (TRU) and 2 Clinical Pathology Division, Institute of Pathology, University of Bern, Murtenstrasse 31, Bern, Switzerland
FP36CD8/CD45RO T-cell infiltration in pre-operative biopsies of colorectal cancer predicts histopathologic features of the matched resection specimen and survival outcome
V. H. Koelzer 1,3, I. Zlobec 1, H. Dawson 1,3, M. Hädrich 2, M. Borner 4, M. Mallaev 1,2, B. Schnüriger 2, D. Inderbitzin 2, A. Lugli 1,3
myhealthcaree-academy telemedical consulting
telemedical
e-academy
„Freitags Kolloquium Pathalogie“, „Tumor-board“, „Team Round“, „HIV-Cup“, „HEP Cup“ sind nur einige Beispiele von Teleme-dical, welche eine virtuelle Plattform für Wissensaustausch mit unterschiedlichen Kliniken und Fachärzten bildet.
Unabhängig davon ob der Fortbildung aus dem Hörsaal, Auditorium, Operationsraum oder an einem externen Symposium statt-�ndet, mit e-academy kommt der Schu-lungsraum zu Ihnen.
Besuchen Sie uns am Stand 2
Die Plattform für medizinische Fortbildungen und Wissenstransfer.
Von der Planung bis zur Umsetzung einer Uni�ed Collobartion Lösung oder bei der Ausstattung von Rapporträumen und Hör-sälen, sind wir Ihr kompetenter Partner.Live Übertragungen von operativen Eingrif-fen oder Symposien ins Internet, werden von unserem Event Team professionell betreut.
consulting
www.myhealthcare.ch | [email protected]
Page
37
FREE
PAP
ER, PO
STER
PRE
SENT
ATIO
NS
1 Translational Research Unit (TRU), Institute of Pathology, University of Bern, Switzerland
2 Department of Visceral Surgery and Medicine, Bern University Hospital, Bern, Switzerland
3 Clinical Pathology Division, Institute of Pathology, University of Bern, Switzerland4 Department of Oncology, Hospital Centre Biel, Biel, Switzerland
FP37Stromal macrophages closely interact with infiltrating tumor cells in the tumor microenvironment of colorectal cancer.
V. H. Koelzer 1,2, K. Canonica 1, H. Dawson 1,2, E. Karamitopoulou 1,2, A. Lugli 1,2, I. Zlobec 1
1 Translational Research Unit (TRU), Institute of Pathology, University of Bern, Switzerland
2 Clinical Pathology Division, Institute of Pathology, University of Bern, Switzerland
FP38 Colorectal cancer patients in two Austrian regions are differentiated by their microRNA expression profiles M. I. Moshammer 1, M. Kalipciyan 1, F. Offner 2, W. Sterlacci 2, G. G. Steger 1, R. M. Mader 1, R. Sedivy 3,4
1 Department of Medicine I, Comprehensive Cancer Center of the Medical University of Vienna, Vienna, Austria
2 Department of Pathology, Landeskrankenhaus Feldkirch, Feldkirch, Austria3 Department of Clinical Pathology, Landesklinikum/Clinical Centre St.Pölten, St.Pölten, Austria
4 Center of Pathology, Danube Private University, Krems/Donau Austria
FP 39Extramural Venous Invasion in Colorectal Cancer Stage I – Precise Assessment by Tangential Tissue Dissection
K. Dirschmid 1, W. Sterlacci 1, M. Rhomberg 1, F. A. Offner 1
1 Department of Pathology, Academic Teaching Hospital Feldkirch, Feldkirch, Austria
die
o
Unified Collaboration Lösung oder bei der
Page
39
FREE
PAP
ER, PO
STER
PRE
SENT
ATIO
NSFP40 High HER2 gene copy number arising in breast cancer after chemotherapy: a challenging situation illustrated through a case report
R. Sarro 1, B. Bisig 1, A. Talamo 1, C. Boéchat 1, S. Guiu 2, M. Fiche 1
1 Institute of Pathology, CHUV, Lausanne, Switzerland2 Deparment of Medical Oncology, CHUV, Lausanne, Switzerland
FP41Tenascin-C Signaling in breast cancer in presence of AVASTINTM™, HERCEPTINTM™ and IRESSATM™ with focus on metaplastic carcinoma
B. Lauss 1, R. Reitsamer 2, S. Swierzcynski 1, I. Llenos 1, G. Hutarew 1, O. Dietze 1 and C. Hauser-Kronberger 1
1 Department of Pathology2 Department of Specialized Gynecology, Salzburger Landeskliniken and Paracelsus Medical University, Muellner Haupstr. 48, Salzburg, Austria
FP42Tumor heterogeneity in primary invasive breast cancer is associated with lymph node metastasis M. Trippel 1, A. Grogg 1, K. Pfaltz 1, C. Tapia 1
1 Institute of Pathology, University of Bern, Bern, Switzerland
FP43 Primary acinic cell carcinoma of the breast: a case report with immunohistochemical evaluation.
A. Maillefer 1, G. Lam 2, S. Monnier 2, M. Pusztaszeri 1
1 Department of Pathology, Geneva University Hospital, Geneva, Switzerland2 Department of Gynecology and Obstetric, Geneva University Hospital, Geneva, Switzerland
PathoWin+, das etablierte Laborinformations- und Administrationssystem für alle Prozesse und Ar-beitsabläufe in der Pathologie.
Ab Oktober 2013 ist PathoWin+ auch für Österreich mit zertifi-
zierter Abrechnung verfügbar!
Basys Data
CH-4102 Binningen
+41 61 683 01 70
NEU
Brings Personal Automation™ to the Pathology Lab.
DNA Extraction Increased Yield: Sufficient Yield for Downstream Amplification Immediate Time Savings: Overnight and 1-hour options for digest Safer Than Other Methods: No Organic Solvents
RNA Extraction NEW Little or no DNA contamination Reliable amplifiable eluates for RT-PCR or next gen sequencing No xylene or other harsh organic necessary
For more information visit: www.promega.com/maxwell
Extract DNA or RNA from thin sections of formalin-fixed paraffin-embedded (FFPE) tissue samples using Promega’s Maxwell® 16 Instrument.
New! FFPE RNA Isolation
Kit
For Research Use Only
Page
41
FREE
PAP
ER, PO
STER
PRE
SENT
ATIO
NSFP44The two sides of the same loins – differentiating between metastatic squamous cell carcinoma of the cervix and a new primary SCC of the lung through HPV PCR and p16.
S. Fontanella 1, R. Fahli 2, I. Letovanec 1
1 Institute of Pathology, Lausanne, Switzerland 2 Institute of Microbiology, Lausanne, Switzerland
FP45Validation of B-plus fixative for molecular studies
A. Nobile 1, B. Bisig 1, L. de Leval 1
1 Institute of Pathology, CHUV, Lausanne, Switzerland
FP46A new fast and highly sensitive assay for the detection of KRAS mutations
A. Riva 1, C. Andersen 2, M. H. Kyneb 3, T. Y. Wollf 3, U. B. Christensen 2, L. Mazzucchelli 1, M. Frattini 1
1 Laboratory of Molecular Pathology, Institute of Pathology, Locarno, Switzerland 2 PentaBase ApS, Odense C, Denmark3 Danish Technological Institute, Life Science Department, Aarhus C, Denmark
FP47Analysis of CD47 expression in acute myeloid leukemia in a bone marrow tissue microarray
S. Galli 1,3, C. Schuerch 1,2, I. Zlobec 1, C. Riether 2, A. Perren 1, A. Ochsenbein 2,3, Y. Banz 1,2
1 Institute of Pathology, University of Bern, Bern, Switzerland 2 Department of Clinical Research, University of Bern, Bern, Switzerland 3 Department of Oncology, University Hospital Bern, Bern, Switzerland
Page
42
FREE
PAP
ER, PO
STER
PRE
SENT
ATIO
NS FP48CD10 expression by a subset of physiological TFH cells is suggestiv that CD10 positivity in angioimmunoblastic T-cell lymphoma (AITL) is not aberrant and reflects ontogeny
S. Hoeller 1,3, P. Amé-Thomas 2, N. Martin-Garcia 1, C. Artchounin 1, C. Copie-Bergman 1, K. Tarte 2, P. Gaulard 1
1 Département de Pathologie, Inserm U955, Hôpital Henri Mondor, Créteil, France 2 INSERM U917, Université Rennes 1, CHU Pontchaillou, Rennes, France 3 University Hospital Basel, Institute of Pathology, University Basel, Basel, Switzerland
FP49Lymphoplasmacytic plaque – a recently recognized lymphoproliferative process – presentation of clinico-pathological features in four childhood and adult cases
T. Zollinger 1, M. Tinguely 1, I. Hegyi 1, M. Pfaltz 1, W. Kempf 1
1 Kempf und Pfaltz Histologische Diagnostik, Zürich, Switzerland
FP50Follicular Lymphoma with Transdifferentiation into Histiocytic Sarcoma
P. Brunner 1, G. Cathomas 1, S. Dirnhofer 2, A. Tzankov 2, N. Willi 1
1 Kantonales Institut für Pathologie, Liestal, Switzerland 2 Institut für Pathologie, Universitätsspital Basel, Switzerland
FP51Isolated Pancytopenia and Bone Pain – An Unsual Presentation of Methotrexate-associated Classical Hodgkin Lymphoma
S. M. Dertinger 1, A. Mader ², G. Höfle ², A. Becherer ³, F. A. Offner 1
1 Institute of Pathology, Academic Teaching Hospital Feldkirch, Austria² Department of Internal Medicine, Landeskrankenhaus Hohenems, Austria³ Department of Nuclear Medicine, Academic Teaching Hospital Feldkirch, Austria
Page
43
FREE
PAP
ER, PO
STER
PRE
SENT
ATIO
NSFP52Papillary Thyroid Carcinoma – How Many Tall Cells Are Needed And – Does BRAF Determine Patient Outcome?
M. Dettmer 1, A. Schmitt 1, H. Steinert 3, D. Capper 2, H. Moch 4, P. Komminoth 5, A. Perren 1
Authors Affiliation(s): 1 Institute of Pathology, University of Bern, Switzerland2 Department of Neuropathology, Institute of Pathology, Ruprecht-Karls University; DKFZ, Heidelberg, Germany
3 Division of Nuclear medicine, University Hospital Zurich, Switzerland4 Institute of Surgical Pathology, University Hospital Zurich, Switzerland5 Institute of Surgical Pathology, Triemlispital, Zürich, Switzerland
FP53Metastatic macrofollicular variant of papillary thyroid carcinoma to lymph nodes: An ambitious diagnosis on frozen section
S. Stadlmann 1, C. Moser 1, R. Rosenberg2, E. Nitzsche 3, G. Singer 1
1 Institute of Pathology, 2 Department of Surgery, 3 Department of Nuclear Medicine, Kantonsspital Baden AG, Baden, Switzerland
FP54Reduced levels of the putative tumor suppressor spinophilin in combination with altered p53 expression are associated with poor prognosis in head and neck cancer
A. M. Aigelsreiter 1, A. Aigelsreiter 2, Th. Bauernhofer 4, A. Gerger 4, M. Halm 4, G. Höfler 2, K. Koller 4, M. Pichler 4, A. L. Ress 4, S. Schauer 2, M. Salzwimmer 5, M. Wehrschuetz 3
1 Institute of Neurosurgery, Medical University of Graz, Austria2 Institute of Pathology, Medical University of Graz, Austria3 Department of Radiology, Medical University of Graz, Austria4 Division of Oncology, Medical University of Graz, Austria5 Department of General Otorhinolaryngology-Head and Neck Surgery, Medical University of Graz, Austria
The best thingthat can happen to a DNA
Bioinformatics•DeNovoAssembly•MappingagainstaReference
Sequence•SNP&ExpressionAnalyses•ContaminationFiltering
•PCRProducts•Plasmids/Fosmids•PrimerWalking•GLP-Compliant Sequencing
Sanger Sequencing•DenovoSequencing•Transcriptomics•Metagenomics•AmpliconSequencing
NextGenSequencing
•DNA/RNAIsolation•PrimerDesignandSynthesis•Real-TimePCR&Genotyping•ProjectOutsourcing
andmanymore…
MicrosynthAGParent CompanySchützenstrasse 15 | 9436 [email protected] | www.microsynth.ch
AUSTRIA
MicrosynthAustriaGmbHa subsidiary of Microsynth AGLeberstrasse 20 | 1110 [email protected] | www.microsynth.at
Switzerland&ROW
SeqlabGmbHa subsidiary of Microsynth AGHannah-Vogt-Strasse 1 | 37085 Gö[email protected] | www.seqlab.de
Austria Germany
Page
45
FREE
PAP
ER, PO
STER
PRE
SENT
ATIO
NSFP55An aggressive hypoxia related subpopulation of melanoma cells is TRP-2 negative
D. Lenggenhager 1*, A. Curioni-Fontecedro 2, M. Storz 1, O. Shakhova 3, L. Sommer 3, D. S. Widmer 4, B. Seifert 5, H. Moch 1, R. Dummer 4, D. Mihic-Probst 1
1 Institute of Surgical Pathology, University Hospital, Zurich, Switzerland* Present address: Institute of Pathology, Cantonal Hospital, St.Gallen, Switzerland2 Department of Oncology, University Hospital, Zurich, Switzerland3 Institute of Anatomy, University of Zurich, Zurich, Switzerland4 Clinic of Dermatology, University Hospital, Zurich, Switzerland5 Division of Biostatistics, Institute of Social and Preventive Medicine, University of Zurich, Zurich, Switzerland
FP56Pseudomyogenic hemangioendothelioma: a distinctive tumor readily mistaken for an epithelioid sarcoma.
J. Gourmaud 1, M. Genevay 1, A. Sanchez 1, A. L. Rougemont 1, E. Saiji 1
1 Service de Pathologie Clinique, Hôpitaux Universitaires de Genève, Geneva, Switzerland
FP57Brown adipose tissue in adults in in cardiovascular, metabolic and cancer diseases – a retrospective autopsy study
A. Aigelsreiter 1, G. Höfler 1, P. Lurf 1
1 Institute of Pathology, Medical University of Graz, Austria
FP58Characteristics of leukocytes in peritubular capillaritis in kidney allografts
N. Kozakowski 1, G. A. Böhmig 2, Z. Kikic 2
1 Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria2 Nephrology and Dialysis, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
Page
46
FREE
PAP
ER, PO
STER
PRE
SENT
ATIO
NS FP59TREX1 mutations – one of the genetic causes for renal vascular diseases in younger patients
H. Hopfer 1, G. Isimbaldi 2, T. Menter 1, M. J. Mihatsch 1, D. T. Winkler 3
1 Institute of Pathology, University Hospital Basel, Basel, Switzerland2 Department of Anatomic Pathology, San Gerardo Hospital, Monza, Italy 3 Department of Neurology, University Hospital Basel, Basel, Switzerland
FP60Morphologic and morphometric analyses of cardiac tissue samples in cardiovascular and cancer diseases- a retrospective autopsy study
A. Aigelsreiter 1, S. M. Bonschak 1, G. Höfler 1, N. Wolf 1
1 Institute of Pathology, Medical University of Graz, Austria
FP61Fatal cardiac perforation by J-tipped guide wire
A. Krauskopf 1, G. Cathomas 1, N. Willi 1
1 Institute of Pathology, Kantonsspital Baselland, Liestal
FP62Establishment of a scoring system for surgical aortic specimens to differentiate between aneurysms of differing aetiology
Y. Banz 1, A. L. Spranger1,2, A. Perren 1, F. Schoenhoff 2, T. Carrel 2
1 Institute of Pathology, University of Bern, Bern, Switzerland2 Department of Cardiovascular Surgery, University Hospital Bern, Bern, Switzerland
Page
29
BÜHLMANN Laboratories AG Phone +41 61 487 12 12Baselstrasse 55 Fax +41 61 487 12 34CH–4124 Schönenbuch/Basel [email protected] www.buhlmannlabs.ch
*EntroGen’s analysis kits require a Real-Time PCR instrument capable of detecting FAM™ and VIC® fluorescent probes.
All the reagents required for the PCR am-plification/detection, as well as validated reaction controls, are included in the kit.
Multianswer Oncology MDx-Testson your* Real-Time PCR Instrument NRASdetects 5 mutations
BRAF (V600E/K/D/R/M)
AKT1 E17K
EGFRdetects 29 mutations
KRAS-BRAFdetects 12 mutations
new!
new!
new!
FP63Primary Angiitis of the Central Nervous System – A Case Study.
Fischer 1, J. Soleman 2, C. Muroi 2, M. Michot 3, M. Diepers 4, L. Remonda 4, J. Fandino 2, R. Grobholz 1
1 Deparment of Pathology, Kantonsspital Aarau, Aarau, Switzerland2 Deparment of Neurosurgery, Kantonsspital Aarau, Aarau, Switzerland3 Medical Intensive Care Unit, Kantonsspital Aarau, Aarau, Switzerland4 Department of Neuroradiology, Kantonsspital Aarau, Aarau, Switzerland
Page
48
PORT
RAITS
OF
THE
ORG
ANIZER
S
Page
49
PORT
RAITS
OF
THE
ORG
ANIZER
SGad Singer graduated from the University of Zürich, Switzerland. After his general pathology training and board certification in surgical pathology in Switzerland he subspecialised in gynecologic pathology, under the mentorship of Robert J. Kurman at the Johns Hopkins Medical Institutions in Baltimore. Gad Singer has contributed to milestone research on molecular pathology of serous ovarian carcinoma. In this context, Gad Singer was awarded the Young Investigator Award of the International Society of Gynecological Pathologists. Gad Singer has authored numerous peer-reviewed papers on ovarian and breast carcinoma. His current research focus remains serous ovarian cancer pathogenesis, progression and chemotherapy response. He is also member of the WHO Committee for Classification of Tumours of the Female Genital Tract (2013). Gad Singer is a professor of pathology at the University of Basel and holds a Swiss board certification in molecular pathology. After four years as attending physician at the Institute of Pathology of the University Hospital in Basel he was appointed to his current position as head of the Institute of Pathology of the Cantonal Hospital Baden, Switzerland. Currently, he is also President of the Board Exam Commission of the Swiss Society of Pathology and Local President of the organizing committee of this Joint Annual meeting of the Swiss and Austrian Societies of Pathology.
Sylvia Stadlmann graduated from the University of Innsbruck, Austria. From 1996–1998 she was post-doctoral research fellow at the Daniel Swarovski Research Laboratory, Department of General- and Transplant Surgery, Innsbruck Medical University, Austria. After her general pathology training and board certification in surgical pathology she subspecialized in cytopathology. Her particular clinical interest is liver pathology and she is co-author of the 3rd edition of the text-book “Pathologie: Leber, Gallenwege und Pankreas“, to be soon published by Springer. Her main research focus is the pathology of the abdominal cavity, mainly the interactions of ovarian carcinoma with the human peritoneum to which she has published many papers. She qualified as a professor at the University of Basel and is head of the Cytopathology Division at the Institute of Pathology of the Cantonal Hospital Baden, Switzerland.
Uwe Rogel graduated in biochemistry from the Heinrich-Heine-University Düsseldorf. During his studies he worked on the identification and characterization of chemotherapy-resistance-associated proteins in tumors from the Ewing‘s sarcoma family. After graduation he worked at the Institute of Pathology of the University Hospital Düsseldorf on various projects, including projects related to the EuroBoNeT Technology Platform (study of bone tumors – Ewing sarcoma and osteosarcoma). He then moved to Baden and works in the molecular pathology lab at the Institute of Pathology of the Cantonal Hospital Baden. There he is involved in routine molecular pathological analyses and research projects on ovarian carcinoma.
Laura Rubbia-Brandt completed her PhD in biology (Faculté des Sciences, Faculté de Médecine Université de Genève) (Prof.G. Gabbiani, Dpt de Pathologie) in 1993 with the thesis „Factors influencing the phenotype of smooth muscle cells and fibroblasts and in particular their expression of alpha smooth muscle actin“. Her thesis for Privat Docent (Faculté de médecine, Université de Genève) in 2002 was „Histopathology of hepatitis C virus infection: implications for pathogenesis in immunocompetent and immunosuppressed host“. Laura Rubbia-Brandt is Director of the Division of Clinical Pathology, Geneva University Hospital Switzerland and full professor in pathology where she teaches GI and liver Pathology at Geneva Medical School. She received her medical education at the University of Geneva, and her specialty training at the Division of Clinical Pathology, Geneva University Hospital Switzerland and Hôpital Beaujon, Paris, France. She is president of the Swiss Hepato-Biliary pathology group, section of the Swiss society of pathology, president of the Swiss society of pathology, active member of the board of the Swiss association of study of liver, referent pathologist of the Swiss Hepatitis C Cohort Study Group, and member of the GI pathology group of the Swiss Institute for Applied Cancer Research, member of the Unites States and Canadian Academy of Pathology (USCAP), Hans Pooper Liver pathology society, and the International Academy of Pathology (IAP). Laura Rubbia Brandt is the author of more than 160 scientific articles, book chapters and reviews. Her research interests are the pathogenesis of hepatic secondary effects neoadjuvant chemotherapy in colorectal metastasis and mechanisms and the role of HCV infection in the development of hepatic steatosis. Currently, she is President of the Swiss Society of Pathology (SSPath/SGPath).
Page
50
PORT
RAITS
OF
THE
ORG
ANIZER
S
Page
51
PORT
RAITS
OF
THE
ORG
ANIZER
SSigurd Lax received his MD from the University of Graz, where he also trained in Pathology (board exam in 1993). After completion of a postdoctoral research fellowship in Gynecological Pathology at the Johns Hopkins University, School of Medicine, in Baltimore, MD (USA) under the mentorship of Prof. R.J. Kurman and LH Ellenson he received his academic lecturership (docent) at the University of Graz and became a tenured faculty member. From 2002 until now he has been head of the new founded Department of Pathology of the General Hospital Graz West, a teaching hospital of the Medical University Graz. His main focus of interest is molecular tumorigenesis of endometrial carcinoma, other fields of interest are mesenchymal tumors of the uterus, epithelial ovarian neoplasm cervical carcinoma and precursors and molecular and surgical pathology of breast carcinoma. He has published around 100 articles in peer reviewed journals, including original publications and reviews and several book chapters. He has been acting as tutor and lecturer of the German division of the IAP and ESGO, is member of the WHO Committee for Classification of Tumours of the Female Genital Tract (2002 and 2013) and on the editorial board of 4 journals. Currently, he is President of the Austrian Society of Pathology and the Austrian Division of IAP (2013-4) and President elect of the German Division of IAP (2015-17).
Pierre-André Diener Pierre-André Diener grew up in St.Gallen, Switzerland and studied medicine at the University of Lausanne. He received his pathology training at the institutes of pathology of the cantonal hospitals in St.Gallen and Lucerne and at the institute of paediatric pathology at the University Clinic of Bonn (Germany). After a year in surgery, he finished his pathology training at the University Hospital in Zurich. Pierre-André Diener has a special interest in gynaecologic pathology, was mentored by Prof. A.B.P. Ng from Sydney, Australia and a particular interest in mesenchymal tumors of the uterus, neoplasms of the ovary and prostate cancer. He was head of the Gynaecological Pathology Lab at the Department of Gynaecology of the University Hospital in Zurich. Since 1992 he has been working as a consultant for Gynaecologic, Urogenital and Paediatric Pathology at the Cantonal Hospital in St.Gallen. Pierre-André Diener was organiser of the 1996 (pathology of the ovary) and 2005 (pathology of the uterine cervix, vagina and vulva) Swiss Society of Pathology / Swiss Division of IAP and co-organiser of the 2010 pathology of the
ovary slide seminars. In the important field of quality assurance in pathology he has authored or co-authored several chapters in the SGPath Guidelines on Quality Assurance and is member of the assessor panel of the UKNEQAS-ICC immunocytochemistry schemes. Pierre-André Diener is member of the Swiss working group of gynaecologic pathology (1990 – 2007 he was president of this group), co-founder of the Swiss working Group of Urogenital Pathology and was reference pathologist for the Swiss Association of Clinical Cancer Research SAKK. He is member of several pathological societies (ESP, PPS, Pathological Society, DGP, BAGP and ISUP). Currently, he is Secretary/Treasurer of the Swiss Society of Pathology.
Kurt Prein received his MD from the University of Graz. After training as a general practitioner he trained in pathology at the General Hospital of Leoben (Styria, Austria). His main focus is routine work in surgical pathology, cytology, microbiology and hospital hygiene. Since 2005 he has been working as a pathologist and a quality manager at the Department of Pathology of the General Hospital Graz West. Currently, Kurt Prein is the secretary of the Austrian Society of Pathology and the Austrian Division of IAP.
Lukas Bubendorf received his medical degree from the University of Basel, Switzerland. After the board certification in Surgical Pathology, he spent a post-doctoral research fellowship at the Cancer Genetics Branch of the National Human Genome Research Institutes at the National Institutes of Health, NIH, Bethesda, MD. During this time, he was directly involved in the invention and first validation of tissue microarray technology. He holds a full professorship and is the head of the Cytopathology Division at the Institute for Pathology of the University Hospital Basel. Dr. Bubendorf has authored more than 150 papers and more than 5 book chapters. His major interests and diagnostic expertise lie within lung pathology and uropathology, and the whole field of cytopathology. The research group of Prof. Bubendorf is currently investigating the role of genomic evolution and heterogeneity in solid tumors including lung and prostate cancer. In cytology, he aims at translating molecular techniques and assays to clinical routine application. He is one of the pioneers of Fluorescence in situ Hybridization (FISH) in cytology.
Page
52
PORT
RAITS
OF
THE
ORG
ANIZER
S
Page
53
PORT
RAITS
OF
THE
INVITE
D SP
EAKE
RSLars Egevad is Professor of Pathology at Karolinska Institutet in Stockholm, Sweden. His main field of interest is prostate pathology. He has authored 190 articles, mainly in urological pathology. Dr Egevad served as scientist at IARC/WHO in Lyon 2006-2008. He has participated in several WHO consensus meetings on prostate pathology and was co-author of the 3rd edition of the WHO Classification of Tumors of the Urinary System and Male Genital Organs. Dr Egevad was Secretary of the International Society of Urological Pathology (ISUP) 2005-2013 and has been the President-Elect of ISUP since 2013. He was in the organizing committee of three ISUP consensus meetings on prostate and renal cancer 2005-2012. He is also a member of the College of American Pathologists (CAP) Review Panel of urological tumors. In 2007 he founded the European Network of Uropathology (ENUP), a communication network with more than 600 members, aiming to coordinate professional activities in this field in Europe. Dr Egevad has given more than 100 invited presen-tations, lectures and platform presentations in 28 countries, organized 29 post-graduate courses in prostate pathology and lectured at 9 post-graduate courses in uropathology in Tokyo and London. In 2008 he was awarded The Koss medal by ISUP for his contributions to urological pathology.
Jonathan Epstein from the Johns Hopkins Medical Institutions (Baltimore, USA) is a recognized leader in the field of urological pathology. He was one of the first investigators to develop a methodical approach to diagnosing limited adenocarcinoma of the prostate on needle biopsy. He lectures widely in the United States and overseas on urological pathology, with emphasis on prostatic and bladder disease, and has written several books and more than 500 articles. He leads the largest Genitourinary Pathology Fellowship in the world and in his function as Director of the Genitourinary Pathology Consult Service at the Johns Hopkins Medical Institutions he receives approximately 15,000 genitourinary pathology consults per year.
Cord Langner from the Institute of Pathology at the Medical University of Graz, Austria, is the Chair of the European Society of Pathology (ESP) working group “Digestive Diseases” and additionally the Founder and Coordinator of the European Network of Gastrointestinal Pathology (ENGIP). His scientific expertise includes gastrointestinal, liver and urogenital pathology. He is author of many original and review articles and also member of the editorial board of several peer-reviewed journals.
Alessandro Lugli is the Head of the Clinical Pathology Division and Vice Chair of the Institute of Pathology at the University of Bern, Switzerland. He is the secretary of the Swiss Association of Gastrointestinal Pathology (SAGIP). His clinical interests include gastrointestinal pathology and post-mortal diagnostics. His research focus lies on colorectal cancer and he is author of over 100 publications and several book chapters. He is a co-founder of the platform “next-generation tissue microarray”(ngTMA) and member of the editorial board of several peer-reviewed journals.
Felix Offner graduated from the University of Innsbruck, Austria and was trained in Pathology at the Medical Universities of Aachen, Germany and Innsbruck. He specialized in the field of GI Pathology at the University of California Los Angeles (UCLA) under Klaus J. Lewin and Wilfred Weinstein. He is Chairman of the Department of Pathology of the Academic Teaching Hospital Feldkirch, Austria. Dr. Offner has about 125 scientific publications. He has a particular interest in the Pathology of the Abdominal Cavity and is co-author of text book “Pathology of the Gastrointestinal Tract and Peritoneum” recently published by Springer. He is president elect of the Austrian Society of Pathology.
Hermann Rogatsch is senior consultant at the Institute of Pathology of the Klagenfurt Hospital in Austria. He received his MD from the University of Innsbruck in 1991. He then trained in Pathology at the University of Innsbruck, where he also worked as associate professor. His main focus of interest is urologic pathology. He has published around 60 articles in peer-reviewed journals.
Robert M. Genta is a professor of Pathology and Medicine (Gastroenterology) at the University of Texas Southwestern Medical Center at Dallas and a staff pathologist at the Veterans Affairs North Texas Health System. He is also the Chief for Academic Affairs at Miraca Life Sciences, a national pathology laboratory based in Irving, Texas, where he manages the world’s largest database of gastrointestinal biopsy specimens. Robert Genta moved in 2006 to Dallas from Geneva, Switzerland, where he was professor of pathology at the University Hospital. He is a member of the Swiss Society of Pathology and continues to cherish his relationship with many Swiss colleagues. Robert Genta has spent the last twenty-five years of his career working on the inflammatory diseases of the stomach, particularly Helicobacter gastritis, exploring both the pathologic and epidemiologic angles. He has contributed more than 300 scientific articles, reviews, and book chapters in these areas.
Paul Komminoth is head of the Institute of Pathology of the City Hospital in Zürich, Switzerland and is Professor of Pathology at the University of Zürich. He has clinical and research interest in endocrine and molecular pathology. He is co-author of several chapters in the WHO books on endocrine, gastrointestinal and soft tissue pathology and was involved in more than 180 original articles and reviews, mainly on endocrine and molecular pathology. His current research interests are the molecular pathology of pancreatic endocrine tumors, thyroid carcinomas and pheochromocytomas. He was in the advisory board of the ENETS (European Neuroendocrine Tumor Society) and is member of the editorial board of the Journal “Endocrine Pathology”.
Page
54
PORT
RAITS
OF
THE
INVITE
D SP
EAKE
RS
Page
55
PORT
RAITS
OF
THE
INVITE
D SP
EAKE
RS
Heinz-Josef Lenz is Professor of Medicine and Professor of Preventive Medicine, holds the Kathryn Balakrishnan Chair for Cancer Research, is Associate Director, Clinical Research, Co-Chair of GI Oncology, Co-Director USC Center for Molecular Pathways and Drug Discover at the University of Southern California Keck School of Medicine and USC/Norris Comprehensive Cancer Center in Los Angeles, California. Dr Lenz received his medical degree from Johannes-Gutenberg Universität in Mainz, Germany, and went on to complete a residency in hematology and oncology at the Eberhard-Karls Universität Tübingen, Germany before completing clerkships in oncology and hematology at George Washington University and the Beth Israel
Hospital of Harvard Medical School, respectively. He completed a postdoctoral Fellowship in the Department of Biochemistry and Molecular Biology at the USC Keck School of Medicine. Dr Lenz’s research focus is in the identification of biomarkers in GI cancers, early drug development and novel clinical trials. He is Co-Chair of SWOG GI Committee, Co-Chair SWOG GI Translational Medicine and member of the NCI GI Steering Committee and NCI Gastroesophageal Task Force and NCI Correlative Science Committee. He is the USC Principal Investigator for NIH U01, N01 and U10.
Glenn McCluggage is consultant Histopathologist in the Royal Group of Hospitals Trust, Belfast and Honorary Professor in Gynaecological Pathology of Queen’s University of Belfast. He has published well over 300 papers in peer reviewed journals, including original publications and many invited editorials and reviews. He is on the Editorial Board of four pathology journals and associate editor of Histopathology. Currently, he is President Elect of International Society of Gynecological Pathologists and was previously secretary of this society. Previously, he was also President of the British Association of Gynaecological Pathologists. He has an extremely busy referral practice and has lectured at many national and international meetings. He has authored or coauthored the various Royal College of Pathologists datasets in the United Kingdom on reporting of gynaecological malignancies. His main diagnostic interests are gynaecological malignancies and the uses of immunohistochemistry in gynaecological pathology.
Elizabeth Montgomery earned her BA in Chemistry from Johns Hopkins University followed by Medical School at George Washington University. She then served in the US Army Medical Corps and completed her AP/CP residency at Walter Reed Army Medical Center followed by active duty tours at Fort Belvoir VA and the Armed Forces Institute of Pathology Soft Tissue Branch. From there she joined the faculty at Georgetown University from 1992-1999. She has been at Johns Hopkins Hospital since 1999, where she has been the Director of Clinical Gastrointestinal Pathology and holds the rank of Professor of Pathology, Oncology, and Orthopedic Surgery. She is an author on over 250 publications, numerous chapters, and of a number of textbooks of gastrointestinal and soft tissue pathology.
Page
56
Iris Nagtegaal gained her biomedical degree (cum laude) in 1996 and her medical degree in 1998 from Leiden University, the Netherlands. Currently, Prof Nagtegaal is Pathologist at the Radboud University Nijmegen Medical Center in the Netherlands. She holds a PhD degree (cum laude) from Leiden University on Pa-thology of Rectal Carcinoma. She has published over 110 papers and has set standards for modern pathology reporting in colorectal cancer, and the evaluation of resection specimens in clinical trials.
Page
57
PORT
RAITS
OF
THE
INVITE
D SP
EAKE
RS
PORT
RAITS
OF
THE
INVITE
D SP
EAKE
RS
Esther Oliva received an MD from the University of Barcelona, where she also trained and completed a board exam in Pathology. After a research fellowship she continued her career at the Mass General in Boston, where she became a faculty member in 1998, Associate Professor in 2003 and Full Professor in 2013. During her whole career she has been dedicated to Gynecological Pathology with particular interest in mesenchymal tumors of the uterus and non-epithelial neoplasms of the ovary. Her intense research activity is reflected by about 200 published articles in peer-reviewed journals and the reception of several scientific awards. In addition, Dr. Oliva is one of the top ranked invited speakers on North American and international conferences. She also has been lecturing several short courses and symposia. Dr. Oliva is member of the editorial board of 12 journals, the World Health Organization (WHO) Committee for Classification of Tumours of the Female Genital Tract, (IARC, Lyon France; 2013) and currently council member of the USCAP.
Sven Perner graduated in Human Medicine in 1999 from the University of Ulm. He then decided to specialize in pathology at the Institute of Pathology, University Hospital of Bonn. From 2004 to 2007, he trained as a Postdoctoral Research Fellow in the lab of Dr. M. Rubin, Brigham and Women‘s Hospital, Harvard Medical School, Boston, MA. Afterwards, Dr Perner joined the Department of Pathology and Laboratory Medicine, Weill Cornell Medical Center, New York, NY as a Research Associate until 2008. Dr. Perner then decided to move back to Germany where he worked as a Junior Research Group Leader at Institute of Pathology, University Hospital Tübingen for 2 years. In 2010, he was appointed Full Professor at the University Hospital of Bonn and since then he has been heading the Department of Prostate Cancer Research at the Institute of Pathology, University Hospital of Bonn. In 2012, he gained a Certification from the National Board
Aurel Perren grew up in Basel and Visp, Switzerland and studied medicine at the University Basel. During his pathology training in Zürich, the interest in neuroendocrine tumors was inspired by Professor Philippe Heitz and Professor Paul Komminoth. His thesis “Clonal analysis of pancreatic endocrine tumors“ was the first project on which he was involved in molecular pathology techniques. After a research fellowship in the Dana Farber Cancer Institute in the Charis Eng lab 1998, Aurel Perren returned to Zürich and led the laboratory of molecular endocrine pathology, responsible for the genetic testing of familial neuroendocrine tumor patients in Switzerland. The histopathological and genetic analysis of familial pNET as a human model for this disease became also his research focus.In 2007, Aurel Perren was appointed Professor for tumor Pathology at the medical faculty of the Technische Universität München, Germany. Since August 2009 Aurel Perren has been Director of the Institute of Pathology of the University Bern. With the foundation of the “translational research unit (TRU)” and of the “tissue bank Bern”, the molecular analysis of human tumor tissue is becoming a main reseach focus of the tumor pathology.Since the first Frascati meeting in 2005 Aurel Perren has regularly been involved in European Neuroendocrine Tumor Society (ENETS) activities. He tries to explain the viewpoint of pathology and genetics in the interdisciplinary discussions. Pathology is and will be even more an important piece of information deciding on patient treatment and the experience of a pathologist is needed in the discussions, as it is needed at tumor board conferences.
of Pathology after completing his specialized pathology training at the University Hospital of Bonn. Sven Perner is currently director of the Department of Prostate Cancer Research and a Full Professor of Pathology at the Institute of Pathology, University Hospital of Bonn. Among others, Dr Perner was awarded the Rudolf-Virchow Prize of the German Society of Pathology in 2010, the Cancer Prize of the state of Württemberg in 2009 and as a member of the Team Science Award of the American Association for Cancer Research in 2007, for his work that has made decisive contributions to the understanding of prostate cancer development. Sven Perner`s main areas of research are in translational cancer research for prostate cancer and lung cancer.
Solange Peters is in charge of the thoracic malignancies program in the Department of Oncology of the University of Lausanne, and active in building a translational program in collaboration with the molecular oncology laboratory directed by Prof. D. Hanahan and Prof. E. Meylan as well as the Ludwig Institute. She has been trained in medical oncology and molecular biology in Switzerland and Italy. Her main field of interest is new biomarker discovery and validation in preclinical and clinical settings. She is also heavily involved and interested in developing multimodality trials for locally advanced NSCLC. She is co-chair of the Swiss lung cancer research group (SAKK), and Scientific Coordinator as well as Chair of the Informatics Committee of the European Thoracic Oncology Platform (ETOP), responsible for communication, trial organization, coordination and related databases since 2012. She is a active in educational programs within ESMO and IASLC, and has been an ESMO Faculty member since 2012. She is also a member of the ESMO E-Learning and CME Working Group (ECWG). She has been elected the Swiss national representative of ESMO in 2013. She is IASLC publication committee member and incoming Publication committee chair as well as member of AACR and EORTC. She is the president of the Swiss education organization Forome, dedicated to cancer multidisciplinary professionals. She was associate editor of Lung Cancer from 2011 to 2012 and became the Deputy Editor of the Journal of Thoracic Oncology (JTO) in 2013. She also acts as associate editor for Frontiers in Pharmacology of Anti-Cancer Drugs and in Thoracic Oncology, and a reviewer for several lung cancer and oncology journals.
Jaime Prat received an MD from University of Madrid and trained in anatomic pathology at The New York Hospital - Cornell Medical College. After completing a postdoctoral fellowship in Surgical Pathology at Memorial-Sloan Kettering Cancer Center also in New York City, he became a faculty member of the Harvard Medical School at the Massachusetts General Hospital and a Junior Faculty Clinical Fellow of the American Cancer Society. Dr. Prat has served as Chairman of the Department of Pathology at Hospital de la Santa Creu i Sant Pau and Professor of Pathology at Autonomous University of Barcelona since 1986. For the last 20 years, he has lectured at many postgraduate courses and has been invited speaker at numerous national and international meetings. He is further a diplomat of the American Board of Pathology in Anatomic Pathology, a fellow the Royal College of
Page
58
Pathologists of Great Britain, and has been on faculty at the USCAP meetings lecturing at three short courses and one long course. He is the author of over 250 publications and serves on multiple editorial boards. His research has focused on clincopathologic features and molecular genetics of gynecological malignancies. Dr. Prat was President of the European Board of Pathology (1999-2004), and President of the International Society of Gynecologic Pathologists (2007-2009). He is also a member of the World Health Organization (WHO) Committee for Classification of Tumours of the Female Genital Tract, (IARC, Lyon France; 2002-), and The International Federation of Obstetricians and Gynecologists (FIGO), Committee on Gynecologic Oncology (2008-).
Page
59
PORT
RAITS
OF
THE
INVITE
D SP
EAKE
RS
PORT
RAITS
OF
THE
INVITE
D SP
EAKE
RS
Robert Riddell graduated from the University of London (St. Bartholomew’s Hospital) and trained in GI Pathology at St. Mark’s and St. Bartholomew’s Hospitals in London. He is currently at Mt. Sinai Hospital in Toronto where he is Head of the Section of Gastrointestinal Pathology and is Professor of Laboratory Medicine and Pathobiology at the University of Toronto. Dr. Riddell has about 250 publications which are largely in gastrointestinal pathology. Many of them are in inflammatory diseases, dysplasia and carcinoma. In 1983, Dr. Riddell was lead author on the paper defining and grading dysplasia in inflammatory bowel disease, a system that is not only still in use but has been extended to other part of the gastrointestinal tract. He has edited or written 5 books, which include a two volume “bible” on gastrointestinal pathology and its clinical implications with Drs. Klaus Lewin and Wilfred Weinstein at UCLA. The second edition of this book is about to come out (late 2013). He is also the lead author of the AFIP Fascicle on tumors of the intestines. Dr. Riddell directs an annual week long gastrointestinal pathology course for ASCP, and speaks frequently both nationally and internationally.
Neil A Shepherd is Professor of Gastrointestinal Pathology and Consultant Histopathologist at Gloucestershire Royal and Cheltenham General Hospitals, Gloucestershire, UK. He is based in the Gloucestershire Cellular Pathology Laboratory in Cheltenham and was the Head of Department until December 2011. He is Past-President and Chairman of the Nominations and Membership Subcommittee of the British Division of the International Academy of Pathology (BDIAP) (2012-4) and served
GENE
RAL
INFO
RMAT
ION
Page
60
PORT
RAITS
OF
THE
INVITE
D SP
EAKE
RS as President (2010-2) and General Secretary (2000-9) of the BDIAP. He holds an Honorary Clinical Professorship at Cranfield University, an Honorary Professorship at the University of Exeter and an Honorary Senior Lectureship at the University of Bristol. He has clinical and research interests in gastrointestinal (GI) pathology. He is a co-author and lead editor of Morson & Dawson‘s Gastrointestinal Pathology, the flagship UK textbook of GI pathology. He has written five other books, over 30 chapters and more than 200 original articles and reviews, mainly on GI pathology. His current research interests are in the influence of pathology on the treatment of colorectal cancer, the clinical and molecular pathology of Barrett‘s oesophagus and bowel cancer screening pathology. He is GI Pathology Specialist Editor for the BDIAP’s journal Histopathology. He is a member of the editorial boards of four other international medical journals.
Gesundheits-Netz Aargau Ost
Spital LeuggernSpital Leuggern
Bez i r k Baden
Reg i on B rugg AG
Gesellschaft und Politik fordern zunehmend
mehr Effizienz im Gesundheitswesen.
Damit Wirtschaftlichkeit, Qualität, Sicherheit
und Patientennähe rund um die Uhr keine
leeren Worthülsen bleiben, lancieren regional
verankerte Institutionen auf der Basis
freiwilliger Kooperationen das «Gesundheits-
Netz Aargau Ost».
Kooperation wirkt.
www.gnao.ch
Workshop Endocrine PathologyWorkshop participation requires pre-registration
AbstractsAbstracts of all accepted presentations (oral and poster presentations) are published in “Der Pathologe”. All particpants receive an abstract book.
Oral presentationsOnly Power Point presentations will be allowed at the sessions. Authors will deliver their presentation to the technician at the TRAFO main hall, at least one hour before the beginning of the Thursday oral presentation, or the day before for the early morning oral presentation on Friday. Oral presentations are a maximum of 8 minutes long, plus a maximum of 2 minutes long for discussion.
LanguageThe official language of all scientific presentations is English.
Speaker preview roomAt the welcome area
PostersPosters will be displayed at the exhibition area. The required dimensions are 118.9 cm (height) x 84.1 cm (width) (so called DIN A0). At the top of the poster the following should be indicated: title, name(s) of the author(s) and affiliation(s). Authors are requested to put up posters on Thursday, November 7, 2013 at 12:30 and to remove it by Friday, November 8, 2013 after free paper presentations III.Authors are asked to be available for questions and discussion at their poster board under following schedule:Posters FP19-39 on Thursday, November 7, 14.45 – 15.45Posters FP40-63 on Friday, November 8, 15.00 – 16.00
Poster prizesA committee will select the best posters for poster prizes.The poster prizes will be presented after the free paper presentations III.
Slide seminarThe seminars are accessible online via: http://pathorama.ch/vcollections.Deadline for submission of the list with suggested diagnoses: November 5, 2013, 19:00. The handout will be available for download: November 6, 2013
Page
62
GENE
RAL
INFO
RMAT
ION
Page
63
GENE
RAL
INFO
RMAT
IONCongress venue
TRAFO BadenBrown Boveri Platz 1CH-5400 BadenSwitzerlandPhone: 056 204 08 88http://www.trafobaden.ch
All scientific sessions will take place in the TRAFO Main Hall (1st floor). The commercial and poster exhibition area is located at the entrance area to the Main Hall and in the „Glassaal“.
Coffee and cateringCoffee and catering will be served at the commercial and poster exhibition areas.
Commercial exhibitionCommercial partners will start to display their products at the exhibit on Thursday, November 7 in the morning and will remove them by 18:30 on Friday, November 8.
WLAN connectionFree WLAN is permanent
Welcome deskThe welcome desk is located at the entrance of the Mall level (1st floor) and will be operated during following hours:
Thursday, November 7: 08.00 – 17.00Friday, November 8: 08.00 – 17.00Saturday, November 9: 08.00 – 12.00
Certificate of attendanceThe certificate of attendance will be handed out at the welcome desk.
CME creditsMeeting: 4 credits per half dayWorkshop: 4 creditsSubmission of workshop slide seminar diagnoses: 3 creditsSlide seminar: 5 creditsSubmission of slide seminar diagnoses: 3 credits
BadgesParticipants are kindly requested to wear their name badges at anytime during the meeting.
Redefining the art of Whole Slide Imaging
Dornacherplatz 7 4500 Solothurn, Switzerland
Phone: +41 (0) 32 625 60 60, Fax: +41 (0) 32 625 60 61
• Ultra-fast scanning - Greatly improved scanning speed (35s at 40x mode for 15 x 15mm sample sizes) and slide capacity of 320 for high throughput laboratories.
• Simple operation - Intuitive slide scanning software and new powerful viewer for fast and easy slide viewing.
• Error free - Robust & stable scanning. Automatic system calibration.
• Blur free - Sharp focus on entire specimen. Dynamic Pre-Focusing (DPF) method and focus scoring.
Applications include• Routine & computer aided diagnosis in pathology laboratory• Research• Education and training• Slide archiving
Learn more at: www.nanozoomer.com
InsuranceThe organizers bear no responsibility for unexpected events related to the participation at the meeting. Participants are advised to take care of their own personal and travel insurance coverage.
Get-together PartyThursday, November 7, 2013 at 19:30 at the TRAFO Main Hall
Gala dinner and showFriday, November 8, 2013 at 19:30 at the TRAFO Main Hall
Show at the gala dinner
Sugar and the JosephinesSwinging and charming entertainment
www.sugarandthejosephines.ch
Page
64
GENE
RAL
INFO
RMAT
ION
VENTANA iScan HTHigh-throughput brightfi eld scannerThe VENTANA iScan HT slide scanner is the most powerful scanner in routine clinical pathology, enabling you to optimize digital pathology with speed, throughput and reliability.
It is fully integrated with the Virtuoso image management and analysis software, making it a complete digital pathology solution.
Roche Diagnostics (Switzerland) Ltd6343 RotkreuzE-Mail [email protected] +41 41 799 61 00www.roche-diagnostics.chwww.ventana.com
VENTANA
Empowering | Innovation
© 2013 VENTANA and iScan HT are trademarks of Roche.
Ventana_iScan-HT_Schweiz_A5_130827_3.indd 1 27.08.2013 16:15:13 Uhr
